E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
Deepak L. Bhatt,Marcus Flather,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon-Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Liz Fabry-Ribaudo,Tingfei Hu,Eric J. Topol,Keith A.A. Fox,Charisma Investigators +24 more
TL;DR: In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin.
Journal ArticleDOI
Prevalence of Asymptomatic SARS-CoV-2 Infection.
Daniel P Oran,Eric J. Topol +1 more
TL;DR: Innovative tactics for public health surveillance, such as crowdsourcing digital wearable data and monitoring sewage sludge, might be helpful to supplement conventional diagnostic testing, which is constrained by capacity, cost, and its one-off nature.
Journal ArticleDOI
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction
Sorin J. Brener,L. Barr,J. E. B. Burchenal,S. Katz,Barry S. George,A. A. Jones,E. D. Cohen,P. C. Gainey,H. J. White,H. B. Cheek,Jeffrey W. Moses,David J. Moliterno,Mark B. Effron,Eric J. Topol +13 more
TL;DR: Patients with acute MI of <12 hours’ duration were randomized to placebo or abciximab if they were deemed candidates for primary PTCA, and the primary efficacy end point was death, reinfarction, or any (urgent or elective) target vessel revascularization (TVR) at 6 months by intention-to-treat (ITT) analysis.
Journal ArticleDOI
A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease
Eric J. Topol,Ferdinand Leya,Cass A. Pinkerton,Patrick L. Whitlow,Berthold Höfling,Charles A. Simonton,Ronald Masden,Patrick W. Serruys,Martin B. Leon,David O. Williams,Spencer B. King,Daniel B. Mark,Jeffrey M. Isner,David R. Holmes,Stephen G. Ellis,Kerry L. Lee,Gordon Keeler,Lisa G. Berdan,Tomoaki Hinohara,Robert M. Califf +19 more
TL;DR: Removing coronary artery plaque with atherectomy led to a larger luminal diameter and a small reduction in angiographic restenosis, the latter being confined largely to the proximal left anterior descending coronary artery.
Journal ArticleDOI
Evaluation of next generation sequencing platforms for population targeted sequencing studies
Olivier Harismendy,Pauline C. Ng,Robert L. Strausberg,Xiaoyun Wang,Timothy B. Stockwell,Karen Beeson,Nicholas J. Schork,Sarah S. Murray,Eric J. Topol,Samuel Levy,Kelly A. Frazer +10 more
TL;DR: This study analyzed human sequence generated by the Roche 454, Illumina GA, and the ABI SOLiD technologies for the same 260 kb in four individuals to provide important insights into systematic biases and data variability that need to be considered when utilizing NGS platforms for population targeted sequencing studies.